Erlotinib-induced purpuric papulopustular eruption treated with pulsed azithromycin
Erlotinib belongs to the targeted cancer treatments acting through epidermal growth factor receptor inhibition. Papulopustular eruption is the most common cutaneous toxicity. The pathogenesis of the rash is not clear. There is no consensus on treatment. In this report, we describe a 73-year-old fema...
| Main Authors: | , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Medknow Publications & Media Pvt Ltd
2016
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4900010/ |